✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Nectar Lifesciences Ltd.

NECLIFE

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹334 Cr.
P/E
0.00

Nectar Lifesciences Ltd.

  • Nectar Lifesciences
  • Haleos Labs
  • Everest Organics
  • TJI Pharma - Small Cap

FAQs on Nectar Lifesciences Ltd. Shareprice

Nectar Lifesciences has given lower returns compared to its competitors.
Nectar Lifesciences has grown at ~-7.2% over the last 8yrs while peers have grown at a median rate of 13.35%

Nectar Lifesciences is not expensive.
Latest PE of Nectar Lifesciences is 0.0, while 3 year average PE is 40.44.
Also latest EV/EBITDA of Nectar Lifesciences is 0.0 while 3yr average is 11.54.

View FAQ's On Business

Growth Table

  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Balance Sheet

  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Cash Flow

  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Quarterly Results

  • Nectar Lifesciences Ltd.
  • Haleos Labs
  • Everest Organics

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Nectar Lifesciences Ltd. Financials

Nectar Lifesciences balance sheet is weak and might have solvency issues

The net debt of Nectar Lifesciences is decreasing.
Latest net debt of Nectar Lifesciences is ₹546 Crs as of Mar-25.
This is less than Mar-24 when it was ₹598 Crs.

No, profit is decreasing.
The profit of Nectar Lifesciences is -₹179.88 Crs for TTM, -₹113.68 Crs for Mar 2025 and ₹5 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Nectar Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech